Skip to content
DraconiticResearch
Search Sources API
220,595 studies31 sourcesUpdated 27 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Gastroenterology

Combined neutrophil-to-lymphocyte ratio and albumin-bilirubin grade predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

  1. 1Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, 20 Geumo-Ro, Yangsan, 50612 Gyeongnam Korea

Abstract

Background: Clinical outcomes after transarterial chemoembolization (TACE) vary considerably among patients with hepatocellular carcinoma (HCC), reflecting the heterogeneity of both tumor biology and underlying liver function. Although systemic inflammatory markers and liver functional reserve have individually been associated with prognosis, the clinical utility of their combined assessment remains unclear. We investigated the prognostic value of combining the neutrophil-to-lymphocyte ratio (NLR) and albumin-bilirubin (ALBI) grade in treatment-naïve patients with HCC undergoing initial TACE.

Methods: We retrospectively analyzed 642 treatment-naïve patients with HCC who received TACE as first-line therapy. Overall survival (OS) was evaluated using the Kaplan–Meier method and Cox proportional hazards regression. Independent prognostic factors were identified by multivariable analysis. Receiver operating characteristic (ROC) curve analysis was performed to compare the prognostic performance of NLR, ALBI grade, and their combination.

Results: During a median OS duration of 41 months, 485 patients (75.5%) died. Multivariable analysis identified Barcelona Clinic Liver Cancer (BCLC) stage (HR 2.070, 95% CI 1.477–2.902; P < 0.001), ALBI grade (HR 1.630, 95% CI 1.248–2.128; P < 0.001), and NLR (HR 1.623, 95% CI 1.195–2.205; P = 0.002) as independent predictors of OS. The combination of ALBI grade and NLR demonstrated modestly improved prognostic discrimination (AUC 0.645) compared with ALBI grade alone (AUC 0.610) or NLR alone (AUC 0.576). Patients with both elevated NLR and impaired liver function exhibited significantly poorer long-term survival than all other subgroups (P < 0.001).

Conclusions: The combination of ALBI grade and NLR provides a simple and readily available prognostic tool that integrates liver functional reserve and systemic inflammatory status. This combined marker improves risk stratification and may serve as a complementary tool for prognostic assessment and clinical decision-making.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05191-9.

Related

  1. Muscle and tissue radiodensity matter: Automated CT-based body composition analysis predicts survival in hepatocellular carcinoma patients undergoing degradable starch microspheres transarterial chemoembolization (DSM-TACE)
    Leonie S. Jochheim, Hannah L. Steinberg, Amos C. Zeller +8
    Therapeutic Advances in Medical OncologyPeer-reviewedCC BYFull textOncologyDOAJ
  2. Case Report: Rapidly fatal hepatic portal venous gas following transarterial chemoembolization for hepatocellular carcinoma
    Renshan Zhao, Bin Xie
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMCEurope PMC
  3. Enhanced Efficacy of Thalidomide‐Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi‐Center Cohort Study
    Jinzhi Xu, Li Song, Yifan Kong +15
    MedCommPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  4. Neoadjuvant transarterial chemoembolization, camrelizumab, and apatinib for centrally located hepatocellular carcinoma (NEO-CENTACT): study protocol for a phase II trial.
    Yang Zou, Junjun Tao, Zhijun Kuang +3
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  5. Lesion selection and external evaluation of clinical-imaging survival models after transarterial chemoembolization for hepatocellular carcinoma
    Z. Xu, A. Melek, E. Castillo +1
    medRxivPreprintCC BYFull textMedical imaging & radiologymedRxiv
BibTeX
@article{hong2026combined,
  title = {{Combined neutrophil-to-lymphocyte ratio and albumin-bilirubin grade predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization}},
  author = {Young Mi Hong},
  journal = {BMC Gastroenterology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12876-026-05191-9},
  url = {https://doi.org/10.1186/s12876-026-05191-9},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Combined neutrophil-to-lymphocyte ratio and albumin-bilirubin grade predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
AU  - Young Mi Hong
PY  - 2026
DA  - 2026/08/12
JO  - BMC Gastroenterology
DO  - 10.1186/s12876-026-05191-9
UR  - https://doi.org/10.1186/s12876-026-05191-9
AB  - Background: Clinical outcomes after transarterial chemoembolization (TACE) vary considerably among patients with hepatocellular carcinoma (HCC), reflecting the heterogeneity of both tumor biology and underlying liver function. Although systemic inflammatory markers and liver functional reserve have individually been associated with prognosis, the clinical utility of their combined assessment remains unclear. We investigated the prognostic value of combining the neutrophil-to-lymphocyte ratio (NLR) and albumin-bilirubin (ALBI) grade in treatment-naïve patients with HCC undergoing initial TACE.  Methods: We retrospectively analyzed 642 treatment-naïve patients with HCC who received TACE as first-line therapy. Overall survival (OS) was evaluated using the Kaplan–Meier method and Cox proportional hazards regression. Independent prognostic factors were identified by multivariable analysis. Receiver operating characteristic (ROC) curve analysis was performed to compare the prognostic performance of NLR, ALBI grade, and their combination.  Results: During a median OS duration of 41 months, 485 patients (75.5%) died. Multivariable analysis identified Barcelona Clinic Liver Cancer (BCLC) stage (HR 2.070, 95% CI 1.477–2.902; P < 0.001), ALBI grade (HR 1.630, 95% CI 1.248–2.128; P < 0.001), and NLR (HR 1.623, 95% CI 1.195–2.205; P = 0.002) as independent predictors of OS. The combination of ALBI grade and NLR demonstrated modestly improved prognostic discrimination (AUC 0.645) compared with ALBI grade alone (AUC 0.610) or NLR alone (AUC 0.576). Patients with both elevated NLR and impaired liver function exhibited significantly poorer long-term survival than all other subgroups (P < 0.001).  Conclusions: The combination of ALBI grade and NLR provides a simple and readily available prognostic tool that integrates liver functional reserve and systemic inflammatory status. This combined marker improves risk stratification and may serve as a complementary tool for prognostic assessment and clinical decision-making.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05191-9.
SN  - 1471-230X
ER  -